Huang Cai, Jin Huan, Zhang Yan, Wang Di, He Ziyi, Shuai Bo
Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
College of Sports Medicine, Wuhan Sports University, Wuhan, China.
Front Pharmacol. 2025 Jun 24;16:1601537. doi: 10.3389/fphar.2025.1601537. eCollection 2025.
Aging-related bone diseases encompass a range of conditions that emerge or worsen with advancing age, including osteoporosis and osteoarthritis, and they are placing an increasing burden on society. Although these diseases differ in clinical manifestations and pathological features, they often share common age-associated mechanisms such as impaired bone remodeling, chronic low-grade inflammation, cellular senescence, oxidative stress, and hormonal changes. Current therapies often face limitations in efficacy or long-term safety, highlighting the need for alternative strategies. Phytochemicals derived from Chinese medicine herb have emerged as promising candidates due to their multi-target effects on bone homeostasis. Oliv. (EU) and its bioactive compounds (e.g., quercetin, aucubin, geniposide, geniposidic acid). may regulate key pathways to restore bone balance, offering potential for treating osteoporosis and other aging-related bone diseases.
This study aims to assess the therapeutic potential of EU in the treatment of aging-related bone diseases.
A literature search was conducted on the PubMed database up to November 2024 using the search term: "Eucommia AND (bone OR cartilage OR joint)."
The review indicates that EU formulas, extracts, and bioactive components promote osteogenesis, suppress bone resorption, and exert anti-inflammatory and antioxidant properties. These effects contribute positively to the treatment of aging-related bone diseases.
The therapeutic benefits of EU support its development as a promising tool for preventing and treating aging-related bone diseases. These findings provide new research directions to address related health challenges associated with population aging.
与衰老相关的骨疾病包括一系列随着年龄增长而出现或恶化的病症，如骨质疏松症和骨关节炎，它们给社会带来了越来越沉重的负担。尽管这些疾病在临床表现和病理特征上有所不同，但它们通常具有共同的与年龄相关的机制，如骨重塑受损、慢性低度炎症、细胞衰老、氧化应激和激素变化。目前的治疗方法在疗效或长期安全性方面往往面临局限性，这凸显了需要替代策略。源自中药的植物化学物质因其对骨稳态的多靶点作用而成为有前景的候选物。杜仲（Eucommia ulmoides Oliv.，EU）及其生物活性化合物（如槲皮素、桃叶珊瑚苷、栀子苷、京尼平苷酸）可能调节关键途径以恢复骨平衡，为治疗骨质疏松症和其他与衰老相关的骨疾病提供了潜力。
本研究旨在评估杜仲在治疗与衰老相关的骨疾病方面的治疗潜力。
截至2024年11月，在PubMed数据库上使用搜索词“杜仲 AND（骨 OR 软骨 OR 关节）”进行文献检索。
综述表明，杜仲配方、提取物和生物活性成分可促进成骨、抑制骨吸收，并具有抗炎和抗氧化特性。这些作用对治疗与衰老相关的骨疾病有积极贡献。
杜仲的治疗益处支持其作为预防和治疗与衰老相关的骨疾病的有前景工具的开发。这些发现为应对与人口老龄化相关的健康挑战提供了新的研究方向。
